Cost Discipline Cue Health has undergone significant headcount reductions and filed for Chapter 7 bankruptcy in 2024, indicating a cost-constrained environment. This suggests potential openness to affordable, scalable diagnostic solutions, managed services, or usage-based pricing models that help preserve budget while maintaining access to at-home testing capabilities.

Diversified Trials The company secured BARDA funding for multiplex respiratory tests and partnered on a US federal contract, signaling a shift toward broader respiratory diagnostics beyond COVID-19. This presents opportunities to position integrated, high-quality testing platforms and connected health data ecosystems for at-home, point-of-care, and provider workflows.

Expansion Opportunities Despite workforce reductions, Cue Health continues to demonstrate strategic partnerships and board appointments, indicating ongoing growth and governance activity. Sales conversations can emphasize scalable deployment across healthcare systems, clinics, and consumer channels, leveraging Cue’s device-enabled lab-quality diagnostics.

Data-Driven Health Cue focuses on real-time, connected health information and consumer control of diagnostics. This creates opportunities to bundle analytics, population health insights, and provider-facing dashboards with the hardware, appealing to health systems and payers seeking actionable data and outcomes-based contracts.

Strategic Partnerships Alliances with investment and advisory entities (Tarsadia Investments) and board-level leadership changes suggest a readiness for strategic collaborations. Targeted use-case partnerships with payers, employers, and healthcare networks could expand adoption, co-development, and revenue diversification for at-home and near-patient testing.